Trial intelligence / Profile preview

ZEAL: Vandetanib + Pemetrexed in Advanced NSCLC

NCT00418886Phase 3Completed

Sponsor
Sanofi
Start
Jan 2007
Primary completion
Sep 2008
Modality
Small Molecules
Countries
21
01

Overview

A Phase 3 trial of vandetanib in non-small cell lung cancer (NSCLC), sponsored by Sanofi. Started Jan 2007; status: completed.

02

Drugs

vandetanib
03

Conditions

non-small cell lung cancer (NSCLC)

Beyond the preview

Go deeper on NCT00418886.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00418886.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call